Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-21-149160
Filing Date
2021-05-04
Accepted
2021-05-04 09:04:11
Documents
16
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d74598d10ka.htm   iXBRL 10-K/A 601770
2 EX-31.3 d74598dex313.htm EX-31.3 4211
3 EX-31.4 d74598dex314.htm EX-31.4 4170
  Complete submission text file 0001193125-21-149160.txt   849550

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eypt-20201231.xsd EX-101.SCH 4978
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eypt-20201231_cal.xml EX-101.CAL 675
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eypt-20201231_def.xml EX-101.DEF 1680
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20201231_lab.xml EX-101.LAB 19737
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20201231_pre.xml EX-101.PRE 15746
9 EXTRACTED XBRL INSTANCE DOCUMENT d74598d10ka_htm.xml XML 8085
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-51122 | Film No.: 21886232
SIC: 3826 Laboratory Analytical Instruments